AdaptiVax-CoV: A Novel Adaptable SARS-CoV2 VLP Vaccine to Produce Broad Humoral and T Cell Responses to S, E and M Viral Proteins

Human Nasal Epithelium Organoids for Assessing Neutralizing Antibodies to a Protective SARS-CoV-2 Virus-like Particle Vaccine

J Carrera Montoya, S Collett, D Fernandez Ruiz, L Earnest, MA Edeling, AHY Yap, CY Wong, JP Cooney, KC Davidson, J Roberts, S Rockman, BM Tran, JL McAuley, G Deliyannis, SL Grimley, DFJ Purcell, SA Waters, DI Godfrey, D Hans, M Pellegrini

2024-03-01

Existing mRNA COVID-19 vaccines have shown efficacy in reducing severe cases and fatalities. However, their effectiveness against ..